Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
2seventy Bio Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.2seventybio.com/...
Year Founded: 2021
Status: Public
Industry Sector: HealthTechnology
CEO: Chip Baird, III, MBA
Number Of Employees: 65
Enterprise Value: $222,483,920
PE Ratio: -4.41
Exchange/Ticker 1: NASDAQ:TSVT
Exchange/Ticker 2: N/A
Latest Market Cap: $259,075,104
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Mar 5, 2025
Management Tracks
CFO Anthony Doyle resigns at Biocryst
Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene
BioCentury | Feb 21, 2025
Deals
With debt looming, Bluebird accepts buyout offer from Carlyle, SK Capital
Incoming CEO Meek would need to drive steep growth in product sales to fulfill highly backloaded deal, with 70% of its value tied up in a CVR
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Aug 19, 2024
Management Tracks
New commercial, regulatory heads at Fulcrum
Plus: Tiziana names Ivor Elrifi CEO, and updates from Soleno, Latigo, Fog and
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | Mar 28, 2024
Data Byte
Eight PDUFA dates on deck in April
J&J and Legend’s CAR T therapy could move into earlier lines; Day One could get its first marketed product
BioCentury | Feb 29, 2024
Management Tracks
Umoja names Russell CFO
Plus: a Playground promotion and updates from CHO Plus and Rapport
BioCentury | Feb 8, 2024
Data Byte
Carvykti now second-biggest seller among CAR Ts
Yescarta still the market leader by a wide margin, as Carvykti, Abecma, Breyanzi await label expansions
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
Items per page:
1 - 10 of 39